Literature DB >> 10319054

Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.

M Ballmann1, P Rabsch, H von der Hardt.   

Abstract

BACKGROUND: Colonisation with Pseudomonas aeruginosa (PA) is a striking feature of lung involvement in cystic fibrosis. To identify the clinical consequences of the different steps of colonisation with PA under a defined therapeutic regime (no prophylactic antibiotic treatment as long as patients had no severe pulmonary disease), their influence on pulmonary function and on therapeutic intensity was examined.
METHODS: Forty patients with cystic fibrosis were followed from first detection of PA (PA1), chronic PA colonisation (PAc), first mucoid PA detection (PAm), to chronic mucoid PA colonisation (PAcm). Percentage predicted forced expiratory volume in one second (FEV1), the number of intravenous antibiotic treatment courses, and the percentage of patients on inhaled antibiotics were followed retrospectively and longitudinally in relation to the different steps of PA colonisation. The annual changes in FEV1 and therapeutic intensity in the two years preceding each step were compared with the two years following each step. Changes in FEV1 were related to therapeutic intensity.
RESULTS: The mean (SD) annual changes in FEV1 (% predicted) worsened significantly only with the transition to the mucoid stages (PAm: 4.6 (13.2) versus -4.3 (8.1); PAcm: 7.3 (12.0) versus -4.8 (7.4)) with a mean difference (95% CI) between before and after the transition of 8.9 (2.6 to 15.2) for PAm and 12.1 (6.4 to 17.6) for PAcm. With non-mucoid PA stages the therapeutic intensity increased in the year of transition and with mucoid PA stages it increased in the years following transition. Therapeutic intensity was unrelated to changes in FEV1.
CONCLUSION: With the treatment regime used an accelerated decrease in FEV1 was successfully prevented in the non-mucoid stages but not in the mucoid stages of PA colonisation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10319054      PMCID: PMC1745320          DOI: 10.1136/thx.53.9.732

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  25 in total

1.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis.

Authors:  L E GIBSON; R E COOKE
Journal:  Pediatrics       Date:  1959-03       Impact factor: 7.124

Review 2.  Management of pulmonary disease in patients with cystic fibrosis.

Authors:  B W Ramsey
Journal:  N Engl J Med       Date:  1996-07-18       Impact factor: 91.245

3.  Denmark to the rescue.

Authors:  R C Stern
Journal:  Pediatr Pulmonol       Date:  1996-03

4.  Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  M E Hodson; A R Penketh; J C Batten
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

5.  Relationship between clinical conditions, radiographic findings and pulmonary functions in patients with cystic fibrosis.

Authors:  R Kraemer; A Rüdeberg; M Kläy; E Rossi
Journal:  Helv Paediatr Acta       Date:  1979

6.  Mucoid Pseudomonas aeruginosa in cystic fibrosis.

Authors:  R L Henry; D C Dorman; J Brown; C Mellis
Journal:  Aust Paediatr J       Date:  1982-03

7.  Changes in the normal maximal expiratory flow-volume curve with growth and aging.

Authors:  R J Knudson; M D Lebowitz; C J Holberg; B Burrows
Journal:  Am Rev Respir Dis       Date:  1983-06

8.  Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.

Authors:  B Frederiksen; C Koch; N Høiby
Journal:  Pediatr Pulmonol       Date:  1997-05

9.  Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.

Authors:  M Szaff; N Høiby; E W Flensborg
Journal:  Acta Paediatr Scand       Date:  1983-09

10.  Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.

Authors:  M E Hodson; C M Roberts; R J Butland; M J Smith; J C Batten
Journal:  Lancet       Date:  1987-01-31       Impact factor: 79.321

View more
  25 in total

1.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Authors:  Michael W Konstan; Patrick A Flume; Matthias Kappler; Raphaël Chiron; Mark Higgins; Florian Brockhaus; Jie Zhang; Gerhild Angyalosi; Ellie He; David E Geller
Journal:  J Cyst Fibros       Date:  2010-11-12       Impact factor: 5.482

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Pseudomonas aeruginosa in children with cystic fibrosis diagnosed through newborn screening: assessment of clinic exposures and microbial genotypes.

Authors:  Don Hayes; Susan E West; Michael J Rock; Zhanhai Li; Mark L Splaingard; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2010-07

Review 4.  Clinical applications of pulmonary delivery of antibiotics.

Authors:  Patrick A Flume; Donald R VanDevanter
Journal:  Adv Drug Deliv Rev       Date:  2014-10-22       Impact factor: 15.470

5.  Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.

Authors:  Michael W Konstan; David E Geller; Predrag Minić; Florian Brockhaus; Jie Zhang; Gerhild Angyalosi
Journal:  Pediatr Pulmonol       Date:  2010-10-20

6.  Pseudomonas infection in antibody deficient patients.

Authors:  Sai S Duraisingham; Steven Hanson; Matthew Buckland; Sofia Grigoriadou; Hilary J Longhurst
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-12-16

7.  Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  Robert Bradley Troxler; Wynton C Hoover; LaCrecia J Britton; Andrea M Gerwin; Steven M Rowe
Journal:  Pediatr Pulmonol       Date:  2012-04-11

8.  Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.

Authors:  S L Heltshe; U Khan; V Beckett; A Baines; J Emerson; D B Sanders; R L Gibson; W Morgan; M Rosenfeld
Journal:  J Cyst Fibros       Date:  2017-10-28       Impact factor: 5.482

9.  Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis.

Authors:  Kathryn E McDougal; Deanna M Green; Lori L Vanscoy; M Daniele Fallin; Michael Grow; Suzanne Cheng; Scott M Blackman; J Michael Collaco; Lindsay B Henderson; Kathleen Naughton; Garry R Cutting
Journal:  Eur J Hum Genet       Date:  2010-01-13       Impact factor: 4.246

10.  A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.

Authors:  Alexander Chuchalin; Eszter Csiszér; Kàlmàn Gyurkovics; Maria Trawińska Bartnicka; Dorota Sands; Nikolai Kapranov; Guido Varoli; Pier Alessandro Monici Preti; Henryk Mazurek
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.